[7] |
Zaika AI,Wei J,Noto JM,et al.Microbial regulation of p53 tumor suppressor[J].PLoSPathog,2015,11(9):e1005099.
|
[8] |
董亮,钱震,施蓉蓉,等.结直肠腺癌组织中P53、HER-2 和Ki-67的表达及其临床病理意义[J].诊断病理学杂志,2015,22(1):19-26.
|
[9] |
刘伟,余英豪,欧阳学农,等.P53和Ki67在胃癌中的表达及其临床意义[J].世界华人消化杂志,2011,19(4):367-373.
|
[1] |
Chen W,Zheng R,Zhang S,etal.Report of cancer incidence andmortality in China,2010[J].Ann TranslMed,2014,2(7):61.
|
[4] |
胃癌HER2检测指南编写组.胃癌HER2检测指南(2011版)[J].中华病理学杂志,2011,40(8):553-557.
|
[5] |
阳帅,张小丽,李亚菲,等.胃癌中HER2蛋白表达及基因扩增的临床意义[J].慢性病学杂志,2015,16(3):277-280.
|
[6] |
王永辉,毛卫波,楼建,等.CD44V6、HER2及Ki67在胃癌和癌旁组织中的表达及相关性分析[J].浙江实用医学,2014,19(3):160-164.
|
[2] |
Moasser MM.The oncogene HER2:its signaling and transforming functions and its role in human cancer pathogenesis [J].Oncogene,2007,26(45):6469-6487.
|
[3] |
Kim KM,Bilous M,Chu KM,et al.Human epidermal growth factor receptor 2 testing in gastric cancer:recommendations ofan Asia-Pacific task force[J].Asia Pac JClin Oncol,2014,10(4):297-307.
|
[10] |
Tolaney SM,Barry WT,Dang CT,et al.Adjuvant paclitaxel and trastuzumab for node-negative,HER2-positive breast cancer[J].N Engl JMed,2015,372(2):134-141.
|
[11] |
李龙,杨继元,杜天幸,等.HER-2表达载体转染对胃癌细胞侵袭、转移及β-catenin分布的影响[J].实用肿瘤学杂志,2015,30(4):340-345.
|
[12] |
Tsuchida K,Murakami H,Doi Y,et al.Clinicopathological features and outcomes of treatment for HER2 positive gastric cancer[J].Gan To Kagaku Ryoho,2015,42(10):1289-1291.
|
[13] |
Penault-Llorca F,Andre F,Sagan C,et al.Ki-67 expression and docetaxelefficacy in patientswith estrogen receptorpositivebreastcancer[J].JClin Oncol,2009,27(17):2809-2815.
|
[14] |
吉国锋,马冲.HER-2/neu基因在胃癌临床研究中的进展[J].中国普外基础与临床杂志,2015,22(6):754-758.
|
[15] |
刘萍,卜海激.胃癌组织中HER-2及Ki-67的表达及相关性[J].临床肿瘤学杂志,2015,20(8):699-703.
|